Listed

Krystal Biotech, Inc.

KRYSNasdaqCIK 1711279HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$119.2mRevenue, Q2 FY2026, three months to 2026-06-30$119.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 3, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$119.2mRevenue, Q2 FY2026, three months to 2026-06-30$119.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Report this figure+24.1% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin49.0%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $58.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Revenue: $119.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Report this figure+8.0 pts on a year earlier
  • Net margin45.9%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $54.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Revenue: $119.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Report this figure+6.0 pts on a year earlier
  • Diluted EPS$1.79Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.79 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Report this figure+38.8% on a year earlier
  • Free cash flow$71.2mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $74.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-03, accession 0001711279-26-000057. Derived: 6-month figure less the 3-month figure.Capital expenditure: $3.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-03, accession 0001711279-26-000057. Derived: 6-month figure less the 3-month figure.Report this figure+40.1% on a year earlier

Last eight quarters

Full statements
Revenue$119.2mOperating margin 49.0%
Diluted EPS$1.79, Q2 FY2026
Free cash flow$71.2m, Q2 FY2026
Krystal Biotech, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m83.8Revenue, Q3 FY2024, three months to 2024-09-30$83.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001711279-25-000087.Report this figure91.1Revenue, Q4 FY2024, three months to 2024-12-31$91.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001711279-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure88.2Revenue, Q1 FY2025, three months to 2025-03-31$88.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-04, accession 0001711279-26-000043.Report this figure96.0Revenue, Q2 FY2025, three months to 2025-06-30$96.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Report this figure97.8Revenue, Q3 FY2025, three months to 2025-09-30$97.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001711279-25-000087.Report this figure107Revenue, Q4 FY2025, three months to 2025-12-31$107.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001711279-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure116Revenue, Q1 FY2026, three months to 2026-03-31$116.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-04, accession 0001711279-26-000043.Report this figure119Revenue, Q2 FY2026, three months to 2026-06-30$119.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%26.8%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $22.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-03, accession 0001711279-25-000087.Revenue: $83.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001711279-25-000087.Report this figure45.4%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $41.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0001711279-26-000016. Derived: 12-month figure less the 9-month figure.Revenue: $91.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001711279-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure41.1%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $36.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-04, accession 0001711279-26-000043.Revenue: $88.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-04, accession 0001711279-26-000043.Report this figure41.0%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $39.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Revenue: $96.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Report this figure42.3%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $41.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-03, accession 0001711279-25-000087.Revenue: $97.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001711279-25-000087.Report this figure41.3%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $44.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0001711279-26-000016. Derived: 12-month figure less the 9-month figure.Revenue: $107.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001711279-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure46.1%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $53.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-04, accession 0001711279-26-000043.Revenue: $116.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-04, accession 0001711279-26-000043.Report this figure49.0%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $58.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Revenue: $119.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Report this figure
Net margin%32.4%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $27.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-03, accession 0001711279-25-000087.Revenue: $83.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001711279-25-000087.Report this figure49.9%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $45.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0001711279-26-000016. Derived: 12-month figure less the 9-month figure.Revenue: $91.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001711279-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure40.5%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $35.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Revenue: $88.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-04, accession 0001711279-26-000043.Report this figure39.9%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $38.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Revenue: $96.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Report this figure81.2%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $79.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-03, accession 0001711279-25-000087.Revenue: $97.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001711279-25-000087.Report this figure48.0%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $51.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0001711279-26-000016. Derived: 12-month figure less the 9-month figure.Revenue: $107.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001711279-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure48.1%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $55.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Revenue: $116.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-04, accession 0001711279-26-000043.Report this figure45.9%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $54.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Revenue: $119.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Report this figure
Diluted EPS$ per share0.91Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.91 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-03, accession 0001711279-25-000087.Report this figurenot reported (Diluted EPS not reported)1.20Diluted EPS, Q1 FY2025, three months to 2025-03-31$1.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-04, accession 0001711279-26-000043.Report this figure1.29Diluted EPS, Q2 FY2025, three months to 2025-06-30$1.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Report this figure2.66Diluted EPS, Q3 FY2025, three months to 2025-09-30$2.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-03, accession 0001711279-25-000087.Report this figurenot reported (Diluted EPS not reported)1.83Diluted EPS, Q1 FY2026, three months to 2026-03-31$1.83 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-04, accession 0001711279-26-000043.Report this figure1.79Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.79 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-03, accession 0001711279-26-000057.Report this figure
Free cash flow$m57.8Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $58.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-03, accession 0001711279-25-000087. Derived: 9-month figure less the 6-month figure.Capital expenditure: $1.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-03, accession 0001711279-25-000087. Derived: 9-month figure less the 6-month figure.Report this figure52.0Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $52.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0001711279-26-000016. Derived: 12-month figure less the 9-month figure.Capital expenditure: $801.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0001711279-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure24.8Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $31.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-04, accession 0001711279-26-000043.Capital expenditure: $6.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-04, accession 0001711279-26-000043.Report this figure50.8Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $52.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-03, accession 0001711279-26-000057. Derived: 6-month figure less the 3-month figure.Capital expenditure: $1.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-03, accession 0001711279-26-000057. Derived: 6-month figure less the 3-month figure.Report this figure38.0Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $39.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-03, accession 0001711279-25-000087. Derived: 9-month figure less the 6-month figure.Capital expenditure: $1.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-03, accession 0001711279-25-000087. Derived: 9-month figure less the 6-month figure.Report this figure75.4Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $77.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0001711279-26-000016. Derived: 12-month figure less the 9-month figure.Capital expenditure: $2.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0001711279-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure73.2Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $80.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-04, accession 0001711279-26-000043.Capital expenditure: $7.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-04, accession 0001711279-26-000043.Report this figure71.2Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $74.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-03, accession 0001711279-26-000057. Derived: 6-month figure less the 3-month figure.Capital expenditure: $3.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-03, accession 0001711279-26-000057. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$389.1mOperating margin 41.5%
Diluted EPS$6.84, FY2025
Free cash flow$188.9m, FY2025
Krystal Biotech, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m0.0Revenue, FY2021, twelve months to 2021-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-26, accession 0001711279-24-000005.Report this figure0.0Revenue, FY2022, twelve months to 2022-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-19, accession 0001711279-25-000008.Report this figure50.7Revenue, FY2023, twelve months to 2023-12-31$50.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001711279-26-000016.Report this figure291Revenue, FY2024, twelve months to 2024-12-31$290.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001711279-26-000016.Report this figure389Revenue, FY2025, twelve months to 2025-12-31$389.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001711279-26-000016.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)(216.2%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$109.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0001711279-26-000016.Revenue: $50.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001711279-26-000016.Report this figure22.6%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $65.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0001711279-26-000016.Revenue: $290.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001711279-26-000016.Report this figure41.5%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $161.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0001711279-26-000016.Revenue: $389.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001711279-26-000016.Report this figure
Net margin%not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)21.6%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $10.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0001711279-26-000016.Revenue: $50.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001711279-26-000016.Report this figure30.7%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $89.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0001711279-26-000016.Revenue: $290.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001711279-26-000016.Report this figure52.6%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $204.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0001711279-26-000016.Revenue: $389.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001711279-26-000016.Report this figure
Diluted EPS$ per share(3.13)Diluted EPS, FY2021, twelve months to 2021-12-31−$3.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-26, accession 0001711279-24-000005.Report this figure(5.49)Diluted EPS, FY2022, twelve months to 2022-12-31−$5.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-19, accession 0001711279-25-000008.Report this figure0.39Diluted EPS, FY2023, twelve months to 2023-12-31$0.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-17, accession 0001711279-26-000016.Report this figure3.00Diluted EPS, FY2024, twelve months to 2024-12-31$3.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-17, accession 0001711279-26-000016.Report this figure6.84Diluted EPS, FY2025, twelve months to 2025-12-31$6.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-17, accession 0001711279-26-000016.Report this figure
Free cash flow$m(116)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$47.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-26, accession 0001711279-24-000005.Capital expenditure: $68.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-26, accession 0001711279-24-000005.Report this figure(154)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$100.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-19, accession 0001711279-25-000008.Capital expenditure: $53.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-19, accession 0001711279-25-000008.Report this figure(101)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$88.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0001711279-26-000016.Capital expenditure: $11.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0001711279-26-000016.Report this figure119Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $123.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0001711279-26-000016.Capital expenditure: $4.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0001711279-26-000016.Report this figure189Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $200.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0001711279-26-000016.Capital expenditure: $12.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0001711279-26-000016.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Krystal Biotech, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
FMR LLC2026-06-30$1.64bn4,418,197Added+44,210
BlackRock, Inc.2026-06-30$1.55bn4,181,432Added+240,976
Avoro Capital Advisors LLC2026-06-30$1.07bn2,888,888Unchanged
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$585.3m1,574,905Added+118,178
STATE STREET CORP2026-06-30$502.2m1,351,158Added+36,724
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$461.1m1,240,567Added+75,243
Soleus Capital Management, L.P.2026-06-30$349.1m939,254Reduced−213,833
Capital World Investors2026-06-30$289.1m777,843Reduced−46,877
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$259.8m698,993Added+55,018
Hood River Capital Management LLC2026-06-30$246.6m663,375Added+43,789

Recent filings

All 507 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Krystal Biotech, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-1511:02 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001711279-26-000064
2026-08-0311:04 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001711279-26-000058
2026-08-0311:03 ET10-QQuarterly reportPeriod 2026-06-300001711279-26-000057
2026-07-2121:24 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001711279-26-000050
2026-05-2000:08 ET8-K5.07 Shareholder vote results0001711279-26-000047
2026-05-0411:07 ET8-K9.01 Financial statements and exhibits0001711279-26-000044
2026-05-0411:06 ET10-QQuarterly reportPeriod 2026-03-310001711279-26-000043
2026-04-0320:31 ETDEF 14AProxy statementPeriod 2026-04-030001711279-26-000036
2026-02-1712:06 ET8-K2.02 Results of operations0001711279-26-000018
2026-02-1712:05 ET10-KAnnual reportPeriod 2025-12-310001711279-26-000016

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 17, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1711279
Tickers
KRYS
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
not reported
Filer category
Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.